Európska únia - litovčina - EMA (European Medicines Agency)

leo pharma a/s - takrolimuzas - dermatitas, atopinis - kiti dermatologiniai preparatai - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. pasitaikančių keturis ar daugiau kartų per metus), kurie turėjo pradinis atsakas į šešių savaičių gydymo du kartus per parą, takrolimuzas tepalas (pažeidimų pašalinta, beveik išvalytas arba mažai įtakos).

Litva - litovčina - SMCA (Valstybinė vaistų kontrolės tarnyba)

ibe pharma, uab - kasos milteliai (proteazė/lipazė/amilazė) - skrandyje neirios tabletės - 240 mg (400 v/10000 v/7500 v); 400 v/10000 v/7500 vnt. - multienzymes (lipase, protease etc.)

Litva - litovčina - SMCA (Valstybinė vaistų kontrolės tarnyba)

ibe pharma, uab - kasos milteliai (proteazė/lipazė/amilazė) - skrandyje neirios tabletės - 240 mg (400 v/10000 v/7500 v); 400 v/10000 v/7500 v - multienzymes (lipase, protease etc.)

Európska únia - litovčina - EMA (European Medicines Agency)

ablynx nv - caplacizumab - purpura, trombozės thrombocytopenic - antitromboziniai vaistai - cablivi fluorouracilu ir folino suaugusiųjų patiria epizodas įsigijo trombozinių thrombocytopenic purpura (attp), kartu su plazmos keistis ir immunosuppression.

Európska únia - litovčina - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psoriazė - imunosupresantais, interleukinas inhibitoriai, - ilumetri fluorouracilu ir folino suaugusiųjų, sergančių vidutinio sunkumo ar sunkia plokštelinės psoriazės, kurie yra kandidatai sisteminės terapijos.

Európska únia - litovčina - EMA (European Medicines Agency)

ceva santé animale - torasemide - aukštos lubos, diuretikai, sulfonamidams, paprastas - Šunys - gydymo klinikinių požymių, susijusi su staziniu širdies nepakankamumu, šunų, įskaitant plaučių edemą.

Európska únia - litovčina - EMA (European Medicines Agency)

dynavax gmbh - hepatito b paviršinis antigenas - hepatitas b - vakcinos - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Európska únia - litovčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioedema, paveldima - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

Európska únia - litovčina - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - imuninės serumai ir imunoglobulinai, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Európska únia - litovčina - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - miego inicijavimo ir priežiūros sutrikimai - psicholeptikai - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.